# EDGAR Filing Document

**Accession Number:** 0000890821
**File Stem:** 0001641172-25-013466
**Filing Date:** 2025-6
**Character Count:** 8177
**Document Hash:** 03869c77ad393f78a7586ae00d4a0ddb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-013466.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001641172-25-013466

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250529

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enveric Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0000890821
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 954484725
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38286
- **FILM NUMBER:** 251020070

**BUSINESS ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL N, SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103
- **BUSINESS PHONE:** 239-302-1707

**MAIL ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL N, SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERI Holdings, Inc.
- **DATE OF NAME CHANGE:** 20150527

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPATIALIZER AUDIO LABORATORIES INC
- **DATE OF NAME CHANGE:** 19950323

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**May 29, 2025**

**Date of Report (Date of earliest event reported)**

**Enveric Biosciences, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38286** | **95-4484725** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**Enveric Biosciences, Inc.**

**4851 Tamiami Trail N, Suite 200**

**Naples, FL 34103**

**(Address of principal executive offices) (Zip code)**

**Registrant's telephone number, including area code: (239) 302-1707**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, par value $0.01 per share | ENVB | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On May 29, 2025, Enveric Biosciences, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting"). A total of 1,206,498 shares of the Company's common stock were present in person or represented by proxy at the 2025 Annual Meeting, which represented 48.81% of the outstanding shares of common stock entitled to vote at the 2025 Annual Meeting and constituted a quorum for the transaction of business. Holders of the Company's common stock were entitled to one vote per share of common stock held as of the close of business on April 4, 2025, the record date for the 2025 Annual Meeting. The matters submitted for a vote and the related results are set forth below. At the Annual Meeting, our stockholders voted on each of the following four matters:

● The election of six directors, to serve until the Company's 2026 annual meeting of stockholders or until their successors are duly elected and qualified ("Election of Directors");

● An advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement (the "Say-on-Pay Proposal");

● The conditional approval to authorize the Company's board of directors to amend the Company's certificate of incorporation, to effect a reverse stock split in the range between 1:5 and 1:50 (the "Reverse Stock Split"), without reducing the number of authorized shares of common stock, at the discretion of the Company's board of directors in the event the Company receives a delisting determination, prior to January 28, 2026, from the Nasdaq Stock Market LLC due to a default of the minimum bid price requirement (the "Conditional Reverse Stock Split Proposal"); and

● The ratification and appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 (the "Auditor Ratification Proposal").

The final vote results for each of these four matters is set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The
 votes cast on the Election of Directors were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **Withheld** | **Broker Non-Votes** |
| Michael D. Webb | 175763 | 155118 | 875617 |
| George Kegler | 148785 | 182096 | 875617 |
| Frank Pasqualone | 174829 | 156052 | 875617 |
| Marcus Schabacker, M.D., Ph.D. | 266476 | 64405 | 875617 |
| Joseph Tucker, Ph.D. | 266855 | 64026 | 875617 |
| Sheila DeWitt, Ph.D | 265640 | 65241 | 875617 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The
 votes cast on the advisory vote for the Say-on-Pay Proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;253,560 | &nbsp;&nbsp;75,850 | &nbsp;&nbsp;1,471 | &nbsp;&nbsp;875,617 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The
 votes cast on the Conditional Reverse Stock Split Proposal were as follows:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** |
| &nbsp;&nbsp;881,471 | &nbsp;&nbsp;301,346 | &nbsp;&nbsp;23,681 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The
 votes cast on the Auditor Ratification were as follows:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** |
| &nbsp;&nbsp;1,082,606 | &nbsp;&nbsp;115,857 | &nbsp;&nbsp;8,035 |

---

For more information about the foregoing proposals, please see the Company's Proxy Statement for the 2025 Annual Meeting. The results reported above are final voting results. No other matters were considered or voted upon at the meeting.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit Number</u> <u>Description</u> <br>104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 3, 2025 | **ENVERIC BIOSCIENCES, INC.** | **ENVERIC BIOSCIENCES, INC.** |
|  | By: | */s/ Joseph Tucker* |
|  |  | Joseph Tucker, Ph.D. |
|  |  | Chief Executive Officer |

---